Metoprolol 25 Mg

Metoprolol tartrate, the active ingredient in Metoprolol 25 Mg, is a selective β1‑adrenergic receptor blocker presented as a 25 mg tablet for oral administration. It is used to manage hypertension, angina pectoris, post‑myocardial infarction care, heart failure and certain cardiac arrhythmias in adult patients.

GNH USA supplies Metoprolol 25 Mg as a licensed, GDP‑compliant product sourced from the European Union, providing reliable access to hospitals, pharmacies and clinics worldwide. The supply chain adheres to stringent quality assurance protocols, ensuring product integrity during global transport.

Metoprolol is a β1‑selective blocker indicated for several cardiovascular conditions.

- Hypertension: reduces blood pressure by decreasing cardiac output and renin release. - Angina pectoris: lowers myocardial oxygen demand, relieving chest pain during exertion. - Post‑myocardial infarction: improves survival and reduces risk of recurrent cardiac events. - Heart failure: enhances symptoms and decreases hospitalization rates by improving ventricular function. - Cardiac arrhythmias: helps control heart rate in atrial fibrillation and other rhythm disorders.

Metoprolol may cause a range of adverse reactions, varying in frequency and severity.

Common Side Effects: - Fatigue: persistent feeling of tiredness that may reduce physical stamina and affect daily activities. - Dizziness: light‑headed sensation, often occurring on standing or sudden posture changes. - Cold extremities: reduced peripheral circulation leading to cool hands and feet. - Gastrointestinal upset: nausea, abdominal discomfort or mild diarrhea that may be transient.

Serious or Rare Side Effects: - Bradycardia: heart rate drops below normal limits, potentially causing faintness, fatigue or chest discomfort. - Heart block: impairment of the heart’s electrical conduction system, which may require medical monitoring or intervention. - Severe bronchospasm: sudden narrowing of the airways, especially in patients with asthma or COPD, leading to breathing difficulty.

When prescribing Metoprolol, clinicians should consider several safety measures to minimize adverse outcomes.

- Monitor blood pressure: check regularly to avoid excessive hypotension, especially after dose changes. - Assess heart rate: observe for bradycardia, particularly in patients with pre‑existing conduction disorders. - Caution in asthma or COPD: β1 selectivity may still affect bronchial tone; use with care in reactive airway disease. - Review concomitant medications: avoid combining with other negative‑chronotropic agents without supervision. - Adjust in renal or hepatic impairment: dose may need reduction based on organ function assessment. - Store at ambient temperature: keep below 25 °C in the original packaging, protected from moisture.

Metoprolol can interact with various medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Combined with other β‑blockers: additive cardiac depression may lead to severe bradycardia or hypotension. - With non‑dihydropyridine calcium channel blockers (verapamil, diltiazem): risk of profound slowing of heart rate and AV‑node block. - With anti‑arrhythmic agents (e.g., amiodarone, sotalol): increased likelihood of conduction disturbances. - With insulin or oral hypoglycemics: may mask hypoglycemia symptoms, requiring closer glucose monitoring. - With potent CYP2D6 inhibitors (e.g., fluoxetine, quinidine): elevated metoprolol plasma concentrations, enhancing adverse effects.

Moderate Interactions (Monitor Closely): - With diuretics: may potentiate hypotensive effect, especially during initial therapy. - With ACE inhibitors or ARBs: additive blood pressure reduction may occur, necessitating dose adjustments. - With NSAIDs: can diminish antihypertensive efficacy, requiring blood pressure monitoring.